Hayat Pharmaceutical Industries Past Earnings Performance
Past criteria checks 4/6
Hayat Pharmaceutical Industries's earnings have been declining at an average annual rate of -8.3%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been declining at an average rate of 0.3% per year. Hayat Pharmaceutical Industries's return on equity is 10.3%, and it has net margins of 17.9%.
Key information
-8.3%
Earnings growth rate
-8.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | -0.3% |
| Return on equity | 10.3% |
| Net Margin | 17.9% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Hayat Pharmaceutical Industries makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 16 | 3 | 6 | 1 |
| 31 Mar 24 | 15 | 2 | 6 | 1 |
| 31 Dec 23 | 16 | 2 | 6 | 1 |
| 30 Sep 23 | 15 | 2 | 6 | 1 |
| 30 Jun 23 | 15 | 2 | 6 | 1 |
| 31 Mar 23 | 17 | 3 | 7 | 1 |
| 31 Dec 22 | 17 | 4 | 6 | 1 |
| 30 Sep 22 | 16 | 3 | 6 | 1 |
| 30 Jun 22 | 15 | 3 | 6 | 1 |
| 31 Mar 22 | 14 | 2 | 6 | 0 |
| 31 Dec 21 | 17 | 4 | 6 | 0 |
| 30 Sep 21 | 18 | 5 | 7 | 0 |
| 30 Jun 21 | 18 | 4 | 7 | 0 |
| 31 Mar 21 | 17 | 4 | 7 | 0 |
| 31 Dec 20 | 17 | 4 | 7 | 0 |
| 30 Sep 20 | 17 | 4 | 6 | 0 |
| 30 Jun 20 | 17 | 4 | 7 | 0 |
| 31 Mar 20 | 17 | 4 | 6 | 0 |
| 31 Dec 19 | 16 | 3 | 6 | 0 |
| 30 Sep 19 | 15 | 3 | 6 | 0 |
| 30 Jun 19 | 14 | 3 | 5 | 0 |
| 31 Mar 19 | 14 | 3 | 5 | 0 |
| 31 Dec 18 | 14 | 3 | 5 | 0 |
| 30 Sep 18 | 13 | 2 | 5 | 0 |
| 30 Jun 18 | 13 | 3 | 5 | 0 |
| 31 Dec 17 | 13 | 2 | 5 | 0 |
| 30 Sep 17 | 13 | 3 | 5 | 0 |
| 30 Jun 17 | 12 | 3 | 4 | 0 |
| 31 Mar 17 | 11 | 2 | 4 | 0 |
| 31 Dec 16 | 11 | 2 | 4 | 0 |
| 30 Sep 16 | 10 | 3 | 3 | 0 |
| 30 Jun 16 | 11 | 2 | 4 | 0 |
| 31 Mar 16 | 11 | 2 | 4 | 0 |
| 31 Dec 15 | 11 | 2 | 4 | 0 |
| 30 Sep 15 | 11 | 2 | 4 | 0 |
| 30 Jun 15 | 11 | 2 | 5 | 0 |
| 31 Mar 15 | 11 | 2 | 5 | 0 |
| 31 Dec 14 | 11 | 2 | 5 | 0 |
| 30 Sep 14 | 10 | 2 | 4 | 0 |
| 30 Jun 14 | 10 | 2 | 4 | 0 |
| 31 Mar 14 | 9 | 2 | 4 | 0 |
| 31 Dec 13 | 10 | 2 | 4 | 0 |
Quality Earnings: HPIC has high quality earnings.
Growing Profit Margin: HPIC's current net profit margins (17.9%) are higher than last year (14.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HPIC's earnings have declined by 8.3% per year over the past 5 years.
Accelerating Growth: HPIC's earnings growth over the past year (32.3%) exceeds its 5-year average (-8.3% per year).
Earnings vs Industry: HPIC earnings growth over the past year (32.3%) exceeded the Pharmaceuticals industry 7.5%.
Return on Equity
High ROE: HPIC's Return on Equity (10.3%) is considered low.